Detalhe da pesquisa
1.
Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
Antimicrob Agents Chemother
; 68(2): e0100423, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092664
2.
Population pharmacokinetics of unbound and total dolutegravir concentrations in children aged 12â years and older: a PK substudy of the SMILE trial.
J Antimicrob Chemother
; 78(4): 1041-1049, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36869720
3.
Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.
AIDS Behav
; 17(1): 193-202, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22584916
4.
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial.
EClinicalMedicine
; 60: 102025, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37304494
5.
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
PLoS One
; 13(4): e0196239, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29684092
6.
Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions.
AIDS
; 27(4): 579-89, 2013 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23135172